Introduction The aim of this study is to determine the efficacy and safety of CyberKnife® (Accuray, Inc., Sunnyvale, CA) hypofractionated radiosurgery (HfRS) in the treatment of chordomas and chondrosarcomas. Methods A total of 24 patients retrospectively identified with chordomas (19 patients) or chondrosarcomas (five patients) were treated between 2012 and 2019 with HfRS as monotherapy or an adjuvant, rescue, or combination therapy. Tumors were located in the skull base (75%) and vertebral spine (25%). Of these, 19 patients underwent previous partial resection and four patients received previous conventional external beam radiation therapy (EBRT) (60-74 Gy). Exclusive or rescue HfRS (20 patients) was administered in five fractions with a median dose of 37.5 Gy (30-40 Gy). Combined tomotherapy-EBRT treatment (median dose: 54 Gy) and HfRS (16.5-30 Gy in 3-12 fractions) were performed in four patients with bulky chordomas. Results The median follow-up from HfRS was 28 months. During clinical follow-up, no deaths were registered with overall survival (OS) of 100% and the actuarial local recurrence-free survival (LRFS) was 93% at one year, 85% at three years, and 68% at five years. Acute toxicity related to HfRS was present in a single patient. Conclusions It is seen that HfRS is effective and safe for chordomas and chondrosarcomas, with rates of LRFS comparable to other radiation modalities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352833 | PMC |
| http://dx.doi.org/10.7759/cureus.17012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study Design: Systematic review.
Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment.
Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours.
Liquid Biopsy for Spinal Tumors: On the Frontiers of Clinical Application.
Global Spine J
January 2025
Combined Neurosurgical and Orthopedic Spine Program, Department of Orthopedics Surgery, University of British Columbia, Vancouver, BC, Canada.
Study Design: Narrative review.
Objectives: This article aims to provide a narrative review of the current state of research for liquid biopsy in spinal tumors and to discuss the potential application of liquid biopsy in the clinical management of patients with spinal tumors.
Methods: A comprehensive review of the literature was performed using PubMed, Google Scholar, Medline, Embase and Cochrane databases, and the review was limited to articles of English language.
Developmental gene expression in skull-base chordomas and chondrosarcomas.
J Neurooncol
December 2024
Department of Neurosurgery, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands.
Purpose: Chordomas are malignant tumors of the axial spine and skull base, and they are notorious for their poor treatment response. Differentiating these tumors from comparatively less malignant chondrosarcomas is crucial for treatment and prognostication. Both tumor types differ in their developmental origin.
View Article and Find Full Text PDFChronic hearing loss turns out being a calcified chondroid mesenchymal neoplasm with FN1::FGFR2 fusion.
Eur Arch Otorhinolaryngol
October 2024
Barmherzige Brüder Klinikum St. Elisabeth Straubing, Klinik für Hals-Nasen-Ohren-Heilkunde mit Kopf-Hals- und plastischer Gesichtschirurgie, Straubing, Germany.
Article Synopsis
- * The tumor, identified as a "calcified chondroid mesenchymal neoplasm" (CCMN) through molecular analysis, was surgically removed, showing extensive changes indicative of its aggressive nature.
- * Follow-up imaging for over two years showed no residual tumor, but ongoing monitoring is crucial due to potential local recurrences; targeted therapies may be considered for any future recurrences involving the FGFR2 fusion.
Spinal chordoma and chondrosarcoma treatment experiences - a 20-year retrospective study from databases of two medical centers.
Sci Rep
October 2024
Divison of Neurosurgery, Departmet of Surgery, National Taiwan University Hospital, No.7, Chung Shan S. Rd. (Zhongshan S. Rd.), Zhongzheng Dist., Taipei, 100225, Taiwan (R.O.C.).
Article Synopsis
- The study analyzed 48 patients with spinal chordoma and chondrosarcoma treated from 2001 to 2023, focusing on the type of surgical margins achieved during tumor removal.
- Patients with negative or microscopically positive margins (R0/R1) had a significantly better overall survival (OS) and progression-free survival (PFS) compared to those with macroscopically positive margins (R2), implying that margin status is crucial for treatment outcome.
- Radiation therapy (RT) did not enhance OS or PFS in either group, leading to the conclusion that en bloc resection surgery with a proper margin is the preferred treatment approach, while radiation may be an option for those unable to have surgery
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!